 | • レポートコード：TPM-BG012 • 出版社/出版日：Transparency Market Research / 2018年7月 • レポート形態：英文、PDF、161ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、血漿交換療法(TPE)の世界市場について調べ、血漿交換療法(TPE)の世界規模、市場動向、市場環境、適応症別（神経障害、腎障害、血液障害、代謝障害）分析、最終用途別（病院、専門クリニック、外来手術センター）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・血漿交換療法(TPE)の世界市場動向 ・血漿交換療法(TPE)の世界市場環境 ・血漿交換療法(TPE)の世界市場規模 ・血漿交換療法(TPE)の世界市場規模：適応症別（神経障害、腎障害、血液障害、代謝障害） ・血漿交換療法(TPE)の世界市場規模：最終用途別（病院、専門クリニック、外来手術センター） ・血漿交換療法(TPE)の世界市場：地域別市場規模・分析 ・血漿交換療法(TPE)の北米市場規模・予測 ・血漿交換療法(TPE)のアメリカ市場規模・予測 ・血漿交換療法(TPE)の中南米市場規模・予測 ・血漿交換療法(TPE)のヨーロッパ市場規模・予測 ・血漿交換療法(TPE)のアジア市場規模・予測 ・血漿交換療法(TPE)の日本市場規模・予測 ・血漿交換療法(TPE)の中国市場規模・予測 ・血漿交換療法(TPE)のインド市場規模・予測 ・血漿交換療法(TPE)の中東市場規模・予測 ・血漿交換療法(TPE)のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global Therapeutic Plasma Exchange Market: Scope and Methodology
This report analyzes the current and future prospects of the global therapeutic plasma exchange market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The report is a combination of primary and secondary research. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global therapeutic plasma exchange market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the overview section. The report also provides insights into the key trends of the therapeutic plasma exchange market such as rise in prevalence of autoimmune diseases, cost advantage over IVIG treatment, and improvement in health care infrastructure in emerging economies. Key market indicators influencing the global therapeutic plasma exchange market, including cost constraints and regulatory landscape, have been taken into consideration. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global therapeutic plasma exchange market.
Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global therapeutic plasma exchange market for each segment is also provided. Additionally, market-related factors such as favorable reimbursement scenario, expanding applications in chronic diseases, side effects associated with plasmapheresis and historical year-on-year growth have been taken into consideration while estimating the market size.
Global Therapeutic Plasma Exchange Market: Segmentation
Based on disease indication, the global therapeutic plasma exchange market has been segmented into neurological disorders, renal disorders, hematology disorders, metabolic disorders, and others. The neurological disorders segment has been classified into chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multiple sclerosis, neuromyelitis optica, and Guillain-Barré syndrome. The renal disorders segment has been categorized into post-renal transplant rejection, anti-glomerular basement membrane (anti-GMB) disease, and Wegener’s granulomatosis. The hematology disorders segment has been divided into thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, cryoglobulinemia, multiple myeloma, metabolic disorders, familial hypercholesterolaemia (homozygous), and fulminant Wilson disease. In terms of end-user, the market has been classified into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment is expected to dominate the market during the forecast period.
In terms of region, the global therapeutic plasma exchange market has been segment into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions in each of the regions. These include the U.S., Canada, the U.K., Germany, Russia, France, Italy, Spain, China, Australia, Japan, India, Brazil, GCC Countries, South Africa, and Mexico.
Global Therapeutic Plasma Exchange Market: Competitive Landscape
The report also profiles major players in the global therapeutic plasma exchange market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melsungen AG, Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, and Medica S.p.A.
The global therapeutic plasma exchange market has been segmented as follows:
Global Therapeutic Plasma Exchange Market, by Disease Indication
Neurological Disorders
Chronic Inflammatory Demyelinating Polyneuropathy
Myasthenia Gravis
Multiple Sclerosis
Neuromyelitis Optica
Guillain-Barré Syndrome
Renal Disorders
Post-renal Transplant Rejection
Anti-GBM (Glomerular Basement Membrane) Disease
Wegener’s Granulomatosis
Hematology Disorders
Thrombotic Thrombocytopenic Purpura
Hemolytic Uremic Syndrome
Cryoglobulinemia
Multiple Myeloma
Metabolic Disorders
Familial Hypercholesterolaemia (homozygous)
Fulminant Wilson Disease
Others
Global Therapeutic Plasma Exchange Market, by End-user
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Global Therapeutic Plasma Exchange Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
Australia & New Zealand
Japan
China
India
Rest of Asia pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa
Section 1 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights
Section 2 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology
Section 3 Executive Summary
3.1 Global Therapeutic Plasma Exchange Market Snapshot
3.2 Market Share Analysis by Region, 2017
Section 4 Market Overview
4.1 Therapeutic Plasma Exchange Market Taxonomy
4.2 Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, 2016–2026
4.3 Global Therapeutic Plasma Exchange Market: Market Outlook
4.4 Key Industry Events
Section 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
5.3 Restraints
5.3.3 Lack of skilled professional
5.4 Opportunities
5.5 Key Trends
5.6 Pipeline Analysis
5.7 Clinical Efficacy of Therapeutic Plasma Exchange in Major Indications
5.8 Global Therapeutic Plasma Exchange (TPE) Market Reimbursement Scenario
5.9 Global Prevalence Rate of Major Diseases
6.0. Healthcare Overview
Section 6 Global Therapeutic Plasma Exchange Market: Number of TPE Procedures, by Country/Sub-region
Section 7 Global Therapeutic Plasma Exchange Market Analysis, by Disease Indication
7.1 Introduction
7.2 Global Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication
7.3 Global Therapeutic Plasma Exchange Market Forecast, by Disease Indication
7.3.1 Neurological Disorders
7.3.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
7.3.1.2 Myasthenia Gravis
7.3.1.3 Multiple Sclerosis
7.3.1.4 Neuromyelitis Optica
7.3.1.5 Guillain-Barré Syndrome
7.3.2 Renal Disorders
7.3.2.1 Post-renal Transplant Rejection
7.3.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
7.3.2.3 Wegener’s Granulomatosis
7.3.3 Hematology Disorders
7.3.3.1 Thrombotic Thrombocytopenic Purpura
7.3.3.2 Hemolytic Uremic Syndrome
7.3.3.3 Cryoglobulinemia
7.3.3.4 Multiple Myeloma
7.3.4 Metabolic Disorders
7.3.4.1 Familial Hypercholesterolaemia (homozygous)
7.3.4.2 Fulminant Wilson Disease
7.3.5 Others
7.4 Market Attractiveness Analysis, by Disease Indication
Section 8 Global Therapeutic Plasma Exchange Market Analysis, by End-user
8.1 Introduction
8.2 Global Therapeutic Plasma Exchange Market Value Share Analysis, by End-user
8.3 Global Therapeutic Plasma Exchange Market Forecast, by End-user
8.3.1 Hospitals
8.3.2 Specialty Clinics
8.3.3 Ambulatory Surgical Centers
8.4 Market Attractiveness Analysis, by End-user
Section 9 Global Therapeutic Plasma Exchange Market Analysis, by Region
9.1 Global Therapeutic Plasma Exchange Market Value Share Analysis, by Region
9.2 Global Therapeutic Plasma Exchange Market Forecast, by Region
9.3 Market Attractiveness Analysis, by Region
Section 10 North America Therapeutic Plasma Exchange Market Analysis
10.1 Market Overview
10.2 Market Analysis, by Disease Indication
10.2.1 Market Value Share Analysis, by Disease Indication
10.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
10.2.2.1 Neurological Disorders
10.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
10.2.2.1.2 Myasthenia Gravis
10.2.2.1.3 Multiple Sclerosis
10.2.2.1.4 Neuromyelitis Optica
10.2.2.1.5 Guillain-Barré Syndrome
10.2.2.2 Renal Disorders
10.2.2.2.1 Post-renal Transplant Rejection
10.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
10.2.2.2.3 Wegener’s Granulomatosis
10.2.2.3 Hematology Disorders
10.2.2.3.1 Thrombotic Thrombocytopenic Purpura
10.2.2.3.2 Hemolytic Uremic Syndrome
10.2.2.3.3 Cryoglobulinemia
10.2.2.3.4 Multiple Myeloma
10.2.2.4 Metabolic Disorders
10.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
10.2.2.4.2 Fulminant Wilson disease
10.2.2.5 Others
10.3 Market Analysis, by End-user
10.3.1 Market Value Share Analysis, by End-user
10.3.2 Market Size (US$ Mn) Forecast, by End-user
10.3.2.1 Hospitals
10.3.2.2 Specialty Clinics
10.3.2.3 Ambulatory Surgical Centers
10.4 Market Analysis, by Country
10.4.1 Market Value Share Analysis, by Country
10.4.2 Market Size (US$ Mn) Forecast, by Country, 2018–2026
10.4.2.1 U.S.
10.4.2.2 Canada
10.5 Market Attractiveness Analysis
10.5.1 By Country
10.5.2 By Disease Indication
10.5.3 By End-user
Section 11 Europe Therapeutic Plasma Exchange Market Analysis
11.1 Market Overview
11.2 Market Analysis, by Disease Indication
11.2.1 Market Value Share Analysis, by Disease Indication
11.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
11.2.2.1 Neurological Disorders
11.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
11.2.2.1.2 Myasthenia Gravis
11.2.2.1.3 Multiple Sclerosis
11.2.2.1.4 Neuromyelitis Optica
11.2.2.1.5 Guillain-Barré Syndrome
11.2.2.2 Renal Disorders
11.2.2.2.1 Post-renal Transplant Rejection
11.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
11.2.2.2.3 Wegener’s Granulomatosis
11.2.2.3 Hematology Disorders
11.2.2.3.1 Thrombotic Thrombocytopenic Purpura
11.2.2.3.2 Hemolytic Uremic Syndrome
11.2.2.3.3 Cryoglobulinemia
11.2.2.3.4 Multiple Myeloma
11.2.2.4 Metabolic Disorders
11.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
11.2.2.4.2 Fulminant Wilson Disease
11.2.2.5 Others
11.3 Market Analysis, by End-user
11.3.1 Market Value Share Analysis, by End-user
11.3.2 Market Size (US$ Mn) Forecast, by End-user
11.3.2.1 Hospitals
11.3.2.2 Specialty Clinics
11.3.2.3 Ambulatory Surgical Centers
11.4 Market Analysis, by Country/Sub-region
11.4.1 Market Value Share Analysis, by Country/Sub-region
11.4.2 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
11.4.2.1 Germany
11.4.2.2 U.K.
11.4.2.3 France
11.4.2.4 Spain
11.4.2.5 Italy
11.4.2.6 Russia
11.4.2.7 Rest of Europe
11.5 Market Attractiveness Analysis
11.5.1 By Country/Sub-region
11.5.2 By Disease Indication
11.5.3 By End-user
Section 12 Asia Pacific Therapeutic Plasma Exchange Market Analysis
12.1 Market Overview
12.2 Market Analysis, by Disease Indication
12.2.1 Market Value Share Analysis, by Disease Indication
12.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
12.2.2.1 Neurological Disorders
12.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
12.2.2.1.2 Myasthenia Gravis
12.2.2.1.3 Multiple Sclerosis
12.2.2.1.4 Neuromyelitis Optica
12.2.2.1.5 Guillain-Barré Syndrome
12.2.2.2 Renal Disorders
12.2.2.2.1 Post-renal Transplant Rejection
12.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
12.2.2.2.3 Wegener’s Granulomatosis
12.2.2.3 Hematology Disorders
12.2.2.3.1 Thrombotic Thrombocytopenic Purpura
12.2.2.3.2 Hemolytic Uremic Syndrome
12.2.2.3.3 Cryoglobulinemia
12.2.2.3.4 Multiple Myeloma
12.2.2.4 Metabolic Disorders
12.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
12.2.2.4.2 Fulminant Wilson Disease
12.2.2.5 Others
12.3 Market Analysis, by End-user
12.3.1 Market Value Share Analysis, by End-user
12.3.2 Market Size (US$ Mn) Forecast, by End-user
12.3.2.1 Hospitals
12.3.2.2 Specialty Clinics
12.3.2.3 Ambulatory Surgical Centers
12.4 Market Analysis, by Country/Sub-region
12.4.1 Market Value Share Analysis, by Country/Sub-region
12.4.2 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
12.4.2.1 China
12.4.2.2 Japan
12.4.2.3 India
12.4.2.4 Australia & New Zealand
12.4.2.5 Rest of Asia Pacific
12.5 Market Attractiveness Analysis
12.5.1 By Country/Sub-region
12.5.2 By Disease Indication
12.5.3 By End-user
Section 13 Latin America Therapeutic Plasma Exchange Market Analysis
13.1 Market Overview
13.2 Market Analysis, by Disease Indication
13.2.1 Market Value Share Analysis, by Disease Indication
13.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
13.2.2.1 Neurological Disorders
13.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
13.2.2.1.2 Myasthenia Gravis
13.2.2.1.3 Multiple Sclerosis
13.2.2.1.4 Neuromyelitis Optica
13.2.2.1.5 Guillain-Barré Syndrome
13.2.2.2 Renal Disorders
13.2.2.2.1 Post-renal Transplant Rejection
13.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
13.2.2.2.3 Wegener’s Granulomatosis
13.2.2.3 Hematology Disorders
13.2.2.3.1 Thrombotic Thrombocytopenic Purpura
13.2.2.3.2 Hemolytic Uremic Syndrome
13.2.2.3.3 Cryoglobulinemia
13.2.2.3.4 Multiple Myeloma
13.2.2.4 Metabolic Disorders
13.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
13.2.2.4.2 Fulminant Wilson Disease
13.2.2.5 Others
13.3 Market Analysis, by End-user
13.3.1 Market Value Share Analysis, by End-user
13.3.2 Market Size (US$ Mn) Forecast, by End-user
13.3.2.1 Hospitals
13.3.2.2 Specialty Clinics
13.3.2.3 Ambulatory Surgical Centers
13.4 Market Analysis, by Country/Sub-region
13.4.1 Market Value Share Analysis, by Country/Sub-region
13.4.2 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
13.4.2.1 Brazil
13.4.2.2 Mexico
13.4.2.3 Rest of Latin America
13.5 Market Attractiveness Analysis
13.5.1 By Country/Sub-region
13.5.2 By Disease Indication
13.5.3 By End-user
Section 14 Middle East & Africa Therapeutic Plasma Exchange Market Analysis
14.1 Market Overview
14.2 Market Analysis, by Disease Indication
14.2.1 Market Value Share Analysis, by Disease Indication
14.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
14.2.2.1 Neurological Disorders
14.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
14.2.2.1.2 Myasthenia Gravis
14.2.2.1.3 Multiple Sclerosis
14.2.2.1.4 Neuromyelitis Optica
14.2.2.1.5 Guillain-Barré Syndrome
14.2.2.2 Renal Disorders
14.2.2.2.1 Post-renal Transplant Rejection
14.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
14.2.2.2.3 Wegener’s Granulomatosis
14.2.2.3 Hematology Disorders
14.2.2.3.1 Thrombotic Thrombocytopenic Purpura
14.2.2.3.2 Hemolytic Uremic Syndrome
14.2.2.3.3 Cryoglobulinemia
14.2.2.3.4 Multiple Myeloma
14.2.2.4 Metabolic Disorders
14.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
14.2.2.4.2 Fulminant Wilson Disease
14.2.2.5 Others
14.3 Market Analysis, by End-user
14.3.1 Market Value Share Analysis, by End-user
14.3.2 Market Size (US$ Mn) Forecast, by End-user
14.3.2.1 Hospitals
14.3.2.2 Specialty Clinics
14.3.2.3 Ambulatory Surgical Centers
14.4 Market Analysis, by Country/Sub-region
14.4.1 Market Value Share Analysis, by Country/Sub-region
14.4.2 Market Size (US$ Mn) Forecast, by Country, 2018–2026
14.4.2.1 GCC Countries
14.4.2.2 South Africa
14.4.2.3 Israel
14.4.2.4 Rest of MEA
14.5 Market Attractiveness Analysis
14.5.1 By Country/Sub-region
14.5.2 By Disease Indication
14.5.3 By End-user
Section 15 Company Profiles
15.1 Competition Matrix
15.3 Company Profiles
15.2.1 Asahi Kasei Corporation
15.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2 Financial Overview
15.2.1.3 Product Portfolio
15.2.1.4 SWOT Analysis
15.2.1.5 Strategic Overview
15.2.2 Baxter International, Inc.
15.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2 Financial Overview
15.2.2.3 Product Portfolio
15.2.2.4 SWOT Analysis
15.2.2.5 Strategic Overview
15.2.3 Terumo Corporation
15.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2 Financial Overview
15.2.3.3 Product Portfolio
15.2.3.4 SWOT Analysis
15.2.3.5 Strategic Overview
15.2.4 B. Braun Melsungen AG
15.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2 Financial Overview
15.2.4.3 Product Portfolio
15.2.4.4 SWOT Analysis
15.2.4.5 Strategic Overview
15.2.5 Fresenius Kabi AG
15.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2 Financial Overview
15.2.5.3 Product Portfolio
15.2.5.4 SWOT Analysis
15.2.5.5 Strategic Overview
15.2.6 Kawasumi Laboratories, Inc.
15.2.6.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2 Financial Overview
15.2.6.3 Product Portfolio
15.2.6.4 SWOT Analysis
15.2.6.5 Strategic Overview
15.2.7 Haemonetics Corporation
15.2.7.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2 Financial Overview
15.2.7.3 Product Portfolio
15.2.7.4 SWOT Analysis
15.2.7.5 Strategic Overview
15.2.8 Cerus Corporation
15.2.8.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2 Financial Overview
15.2.8.3 Product Portfolio
15.2.8.4 SWOT Analysis
15.2.8.5 Strategic Overview
15.2.9 Hemacare Corporation
15.2.9.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2 Financial Overview
15.2.9.3 Product Portfolio
15.2.9.4 SWOT Analysis
15.2.9.5 Strategic Overview
15.2.10 Medica S.p.A.
15.2.10.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2 Financial Overview
15.2.10.3 Product Portfolio
15.2.10.4 SWOT Analysis
15.2.10.5 Strategic Overview
Table 01: Global Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Region, 2017
Table 02: Global Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Disease Indication, 2017
Table 03: North America Therapeutic Plasma Exchange Market Size (US$ Mn), by Country and Number of TPE Procedures, 2017
Table 04: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
Table 05: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
Table 06: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
Table 07: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
Table 08: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 09: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 10: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 11: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 12: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 13: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 14: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 15: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication,
Table 16: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 17: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 18: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 19: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 20: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 21: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 22: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2026
Table 23: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders,
Table 24: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 25: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders,
Table 26: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 27: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 28: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 29: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 30: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 31: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 32: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 33: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 34: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 35: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 36: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 37: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 38: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 39: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 40: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 41: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 42: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 43: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2026
Table 44: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 45: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 46: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 47: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 48: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 49: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2016–2026